Emergent BioSolutions Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2025, directors and officers (as defined in Exchange Act Rule 16a-1(f)) of the Company adopted written plans for the sale of the Company’s common stock intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (“Rule 10b5-1 trading arrangements”) as set forth in the table below.
| Name | Position | Action | Adoption date | Rule 10b5-1 Trading Plan Provides for Purchase/Sale (1) | Total Shares of Common Stock to be Sold | Expiration Date (2) |
|---|---|---|---|---|---|---|
| Kathryn Zoon | Director | Adoption | May 16, 2025 | Sale | 24,286 | May 15, 2026 |
| (1) Sales may begin on the 91st day following the adoption of the Rule 10b5-1 trading arrangement. | ||||||
| (2) Subject to early termination in accordance with the terms of the Rule 10b5-1 trading arrangement. | ||||||
The above-named director is currently and is expected to remain in compliance with share ownership guidelines following the sale of any common shares pursuant to her Rule 10b5-1 trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.